Integra LifeSciences Reports First Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Dow, S&P 500 fall, tech steadies to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude jumps to highest since April on Houthi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
Oppenheimer Downgrades Integra LifeSciences (IART) to Perform
May 7, 2024 6:09 AM EDTOppenheimer analyst Steven Lichtman downgraded Integra LifeSciences (NASDAQ: IART) from Outperform to Perform.
The analyst comments "Following an announced delay in manufacturing restart at IART's Boston facility, we are downgrading IART shares from Outperform to Perform and removing our $51 price target. As a... More
Integra LifeSciences (IART) PT Lowered to $26 at BofA Securities
May 7, 2024 5:38 AM EDTBofA Securities analyst Craig Bijou lowered the price target on Integra LifeSciences (NASDAQ: IART) to $26.00 (from $42.00) while maintaining a Underperform rating.
The analyst comments "The new findings from the Boston facility audit are the latest in a series of setbacks... More



